CD274 and colorectal carcinoma: Avelumab is a PD-L1 inhibitor that is currently approved for use in metastatic Merkel cell carcinoma and urothelial carcinoma that is being tested in combination with Cetuximab and Irinotecan for metastatic MSS CRC (NCT03608046).